Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Lilly, Osaka Univ. Join Forces on Obesity Research
September 2, 2016
- Chugai Transfers Marketing Authorization for Vesanoid to Fuji Pharma
September 2, 2016
- Sunovion to Acquire Canadian CNS Biotech: Sumitomo Dainippon
September 2, 2016
- Kipres/Singulair AG Hits Shelves in Japan: Kyorin Holdings
September 2, 2016
- Sandoz Taps Jason Hoffe as New Japan Head
September 2, 2016
- Otsuka, RIKEN Open Collaborative Research Center to Promote Regenerative Medicine
September 2, 2016
- Takecab Most Heavily Pitched Drug in July: Anterio
September 1, 2016
- Sovaldi Filed in Japan for All Hep C Genotypes Excluding Genotype 1: Gilead
September 1, 2016
- Pfizer Files Xalkori for ROS1-Positive Lung Cancer in Japan
September 1, 2016
- Harvoni Outstrips Plavix to Top FY2015 Japan Sales Ranking: Jiho Tally
September 1, 2016
- Kyowa Kirin Completes Construction of API Manufacturing Facility for Biopharmaceuticals
September 1, 2016
- Lonsurf Now Available in UK with Health Coverage: Taiho
August 31, 2016
- Data Support Lixiana’s Efficacy in AF Patients Undergoing Cardioversion
August 31, 2016
- Mitsubishi Tanabe’s ALS Drug Gets PDUFA Date of June 16, 2017
August 31, 2016
- Sumitomo Dainippon to Shed Jobs for Leaner Japan Operations
August 31, 2016
- Lilly to Withdraw Taltz from Wholesaler Inventory; Distributor Execs Irked by MHLW’s Price Handling
August 31, 2016
- Santen, Kerui Set Up Ophthalmic JV in China
August 31, 2016
- Oropharyngeal Candidiasis Drug Hits Primary Endpoint in PIII: Sosei
August 30, 2016
- Seikagaku, Ferring Finalize Licensing Deal for Lumbar Disc Herniation Drug
August 30, 2016
- Nichi-Iko Completes Tender Offer for Sagent
August 30, 2016
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…